Clinical trials: sponsored by Samsung Medical Center
Cardiopulmonary Arrest
Usefulness of the Evaluation of the ROSC With Carotid Ultrasound During CPR
The current cardiopulmonary resuscitation(CPR) guidelines recommend that the heart rhythm be checked every two minutes during CPR for cardiac arrest patients.
- Trial name
- NCT04793386
- Testing
- carotid ultrasound
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- Samsung Medical Center
Non-small Cell Lung Cancer
Adjuvant CCRT vs CT in Minimal N2 NSCLC
This study propose adjuvant concurrent chemoradiotherapy vs chemotherapy alone in completely resected microscopic N2 NSCLC
- Trial name
- NCT01066234
- Testing
- concurrent chemoradiotherapy, chemotherapy only
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Samsung Medical Center
Head and Neck Cancer
Concomitant Chemoradiotherapy (CCRT) With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer
This phase II trial is evaluating the efficacy of concurrent chemoradiation therapy with weekly docetaxel and cisplatin combination regimen.
- Trial name
- NCT01126008
- Testing
- CCRT with weekly docetaxel & cisplatin
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Samsung Medical Center
Thymic Epithelial Tumor
neoadjuvant_thymic Epithelial Tumor
This is a Phase II single center, open-label, single arm study in patients with unresectable thymic epithelial tumors (Masaoka stage III, IVA).
- Trial name
- NCT03858582
- Testing
- pembrolizumab, Radiation
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Lung Cancer
Personalized Sequence for Thoracic, Esophageal, and H&N Cancer
The next generation of personalized medical treatment according to the type of personal genetic information are evolving rapidly.
- Trial name
- NCT02299622
- Testing
- Genetic test
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Non-small Cell Lung Cancer
Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib
The program will provide early access to the investigational drug gilotrif in patients with advanced non-small cell lung cancer who have failed at least 6 months on erlotinib or gefitinib.
- Trial name
- NCT02747953
- Testing
- Gilotrif
- Volunteers
- 50 people
- Sponsor
- Samsung Medical Center
Small Cell Lung Cancer
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients
AZD1775 (previously known as MK-1775 in earlier studies) is an inhibitor of Wee1, a protein tyrosine kinase. Wee1 phosphorylates and inhibits cyclin-dependent kinases 1 (CDK1) and 2 (CDK2), and is involved in regulation of the…
- Trial name
- NCT02593019
- Testing
- AZD1775
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Samsung Medical Center
Lung Cancer
Development of Patient Tailored Guideline of Physical Activity for Lung Cancer
This study aims to propose a perioperative comprehensive intervention based on health behavior model to improve cardiopulmonary function and quality of life among lung cancer patients following
- Trial name
- NCT03215537
- Testing
- comprehensive intervention
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Samsung Medical Center
Cervical Cancer
Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy
This is an exploratory, open label, multi-center trial to evaluate the safety and efficacy of combination of durvalumab with BVAC-C in patients with cervical cancer refractory to or relapse after platinum-based first-line…
- Trial name
- NCT04800978
- Testing
- BAVC-C+Durvalumab
- Volunteers
- 37 people
- Sponsor
- Samsung Medical Center
Infection
Respiratory Protection Effect of Ear-loop-type KF94 Mask
Ear-loop-type Korean Filter 94 masks (KF94 masks, equivalent to the N95 and FFP2) are broadly used in health care settings in Korea for the COVID-19 pandemic.
- Trial name
- NCT04794556
- Testing
- tight-fitting of KF94 mask with clip
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Stroke
A Study on Brain Activity During Transcranial Direct Current Stimulation in Stroke Patients
The purpose of this study is to identify the characteristics of neural plasticity seen in stroke patients by measuring the changes in brain activity during stimulation using functional near-infrared spectroscopy (fNIRS) when…
- Trial name
- NCT04549753
- Testing
- Transcranial direct current simulation
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Pancreas Cancer
Development of a Prediction Platform for Neoadjuvant Treatment and Prognosis in Pancreatic Cancer Using Organoid
The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process.
- Trial name
- NCT04777604
- Testing
- Organoid
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Samsung Medical Center
SCLC
Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]
This study is a single arm, multi-center phase II study of AZD6738 and olaparib combination therapy in patients with relapsed small cell lung cancer (SCLC) as a second or third line chemotherapy.
- Trial name
- NCT03428607
- Testing
- AZD6738, Olaparib
- Where
- South Korea
- Volunteers
- 26 people
- Sponsor
- Samsung Medical Center
Small Cell Lung Cancer
Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations
This study is a single arm, multi-center phase II study of olaparib monotherapy in patients with relapsed small cell lung cancer (SCLC) harboring HR pathway gene mutations not limited to BRCA 1/2 mutations, ATM deficiency or…
- Trial name
- SUKSES-B (NCT03009682)
- Testing
- Olaparib
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Samsung Medical Center
Melanoma
Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.
This is a Phase 2, single center study to evaluate the efficacy, safety of nivolumab in combination with radiation therapy in patients with mucosal melanoma of the head and neck (MMHN).
- Trial name
- NCT03758729
- Testing
- Nivolumab, Radiation Therapy
- Sponsor
- Samsung Medical Center
Pancreatic Cancer Resectable
Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Resected Pancreatic Cancer Using Organoid
The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process.
- Trial name
- NCT04736043
- Testing
- Organoid
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Samsung Medical Center
Eisenmenger Complex
Real World Difference After Changing Medication From Nonselective to Selective Endothelin Receptor Antagonist in Stable Eisenmenger Syndrome
In this study, the investigator will evaluate the treatment effects and safety, patient compliance of Ambrisentan in Eisenmenger syndrome in PAH patients who have been previously treated with Bosentan.
- Trial name
- NCT04732650
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Non Small Cell Lung Cancer, Brain Metastases
Central Nervous System(CNS) Efficacy of Dacomitinib
This is a single-arm, phase II study of dacomitinib in advanced EGFR-mutant NSCLC patients who have non-irradiated brain metastasis.
- Trial name
- NCT04675008
- Testing
- Dacomitinib
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Esophageal Squamous Cell Carcinoma
Neoadjuvant Nivolumab for Operable Esophageal Carcinoma
This is a single arm phase II study, in which maximum 3 cycles of nivolumab (240 mg fixed dose every 2 weeks) is administered for T2- or T3-node negative esophageal squamous cell carcinoma, before curative operation.
- Trial name
- NCT03987815
- Testing
- Nivolumab
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Samsung Medical Center
Esophageal Squamous Cell Carcinoma
Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer
This is a single arm phase II study, in which 2 cycles of chemotherapy (5FU/CDDP) and immunotherapy (durvalumab and tremelimumab) are administered every 3 weeks with concurrent radiotherapy for inoperable locally advanced…
- Trial name
- NCT03377400
- Testing
- Durvalumab
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center